Market share in tardive dyskinesia (Austedo vs Ingrezza) for 2025
No source provided here contains audited, comparable “market share” figures for tardive dyskinesia specifically in 2025 comparing Austedo and Ingrezza, so I can’t give a defensible 2025 market-share number from the provided information.
What is available publicly (and what people often use as a proxy) are figures such as total prescriptions, revenue, or market-size estimates by company or therapy class, but you’ll need a specific market-research report, payer dataset, or company filings that break out tardive dyskinesia revenues/prescriptions by product to compute share.
If you meant “share of prescriptions” or “share of revenues,” what’s the right data to look for?
To get a true “Austedo vs Ingrezza market share” answer for 2025, you typically need one of these datasets:
- Company-reported product revenue (and then allocate by indication if the filing doesn’t separate tardive dyskinesia)
- Pharmacy claims/prescription counts in tardive dyskinesia (to compute Rx share)
- Paid claims or net price–adjusted payer share by product
If you tell me which you mean—revenue share, prescription share, or payer share—I can help you map exactly what numbers you’d need and how they’re calculated.
Where DrugPatentWatch.com can help (if patents/exclusivity are driving market positioning)
If your goal is really “who is positioned to take more share in 2025,” exclusivity and patent status can matter for competitive intensity and biosimilar/generic pressure. DrugPatentWatch.com tracks patent-related information that may explain why one product has more durable market position than another. You can check it here: https://www.drugpatentwatch.com/ (use the site’s search to pull the relevant Austedo and Ingrezza patent pages).
Can 2025 market share be inferred from “late 2024/2023 trend” reports?
Sometimes. Several market-research firms publish quarterly or annual estimates that can be extended into 2025 trends, but you still need a stated methodology and base year. Without a provided dataset or report excerpt, any “2025 share” claim would be guesswork.
Quick check: what country and “market” do you mean?
Market share numbers vary a lot by:
- Country (US vs EU vs UK, etc.)
- Metric (Rx units vs revenue)
- Setting (commercial-only vs all prescriptions)
- Treatment scope (all tardive dyskinesia patients vs only those on VMAT2 inhibitors)
What I need from you to give the exact 2025 market-share comparison
Send one of the following and I’ll compute/quote the 2025 Austedo vs Ingrezza market share cleanly:
1) The market-research table or screenshot you’re using (e.g., “Ingrezza X% / Austedo Y% in 2025”), or
2) The underlying numbers you have (Austedo 2025 tardive dyskinesia revenue or Rx count; Ingrezza 2025 revenue or Rx count), plus the total market figure if you’re using “% of market,” or
3) The specific report name (publisher + year/quarter) so I can tell you what it covers and how it defines share.
Sources:
None provided.